Articles
October is Breast Cancer Awareness Month—a time to educate people about early cancer detection, novel breast cancer treatments, and ways to support survivors. Today’s educational efforts will aid generations to come and positively influence the following breast cancer statistics. Read More ›
Only 4.8% of Web sites describing prostate cancer were written at the National Institutes of Health recommended reading level. Read More ›
Over one-third of the 12.6 million cancer survivors in the United States face physical or mental issues that put their overall health in danger. Read More ›
Patients’ happiness is diminished based on the degree to which a disease disrupts daily functioning, according to a new study. Read More ›
Timing of end of life (EOL) care discussions affects decisions about EOL care. Read More ›
Men with prostate cancer who receive androgen deprivation therapy may, in all likelihood, suffer from fatigue if they have single nucleotide polymorphisms (SNPs) in 3 proinflammatory genes. Read More ›
The Cancer Institute of New Jersey (CINJ) is 1 of 41 National Cancer Institute‒designated Comprehensive Cancer Centers in the United States. CINJ delivers advanced comprehensive care to adults and children, and CINJ investigators are heavily involved in research. Read More ›
Ovarian cancer is the fifth leading cause of cancer-related death in females in the United States.1 There will be an estimated 22,280 new cases and 15,500 deaths related to ovarian cancer in 2012.1 The prognosis of advanced ovarian cancer is poor, with a 5-year survival rate of 5% to 20%. A platinum-based doublet chemotherapy post cytoreductive surgery has been the standard of care for the past decade. Read More ›
Meta-Analysis Actually Shows Fewer Serious
Adverse Events
Ameta-analysis reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) supports the new guidelines that recommend weight-based chemotherapy dosing for obese cancer patients.1,2 Read More ›
Ameta-analysis reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) supports the new guidelines that recommend weight-based chemotherapy dosing for obese cancer patients.1,2 Read More ›
Although preliminary, a recent experimental study published online in the journal Genetics (Wallace MD, et al. Genetics. 2012;192:
385-396) found that lack of the neurofibromin 1 (NF1) gene was observed in more than 1 of every 4 experimentally induced breast cancers. The study findings also suggest that tamoxifen will not be effective in cancers that lack the NF1 gene. Read More ›